Scarica l'app Stockscreener
5.36
3.68%
0.19
Pre-mercato:
5.41
0.05
+0.93%
Precedente Chiudi:
$5.17
Aprire:
$5.13
Volume 24 ore:
925.99K
Relative Volume:
0.94
Capitalizzazione di mercato:
$508.56M
Reddito:
-
Utile/perdita netta:
$-75.43M
Rapporto P/E:
-4.3931
EPS:
-1.2201
Flusso di cassa netto:
$-72.75M
1 W Prestazione:
-4.80%
1M Prestazione:
+57.65%
6M Prestazione:
+10.97%
1 anno Prestazione:
+374.34%
Intervallo 1D:
$5.03
$5.43
Intervallo di 1 settimana:
$4.94
$6.01
Portata 52W:
$1.08
$7.44
Zura Bio Ltd Stock (ZURA) Company Profile
Nome
Zura Bio Ltd
Settore
Industria
Telefono
858-247-0520
Indirizzo
4225 EXECUTIVE SQUARE, LA JOLLA
Compare ZURA vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ZURA
Zura Bio Ltd
|
5.36 | 559.80M | 0 | -75.43M | -72.75M | -1.2201 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Zura Bio Ltd Stock (ZURA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-09 | Iniziato | Wedbush | Outperform |
| 2024-11-04 | Iniziato | Leerink Partners | Outperform |
| 2024-09-05 | Iniziato | H.C. Wainwright | Neutral |
| 2024-05-03 | Iniziato | Piper Sandler | Overweight |
| 2023-10-10 | Iniziato | Ladenburg Thalmann | Buy |
| 2023-08-25 | Iniziato | Oppenheimer | Outperform |
| 2023-06-22 | Iniziato | Guggenheim | Buy |
| 2023-06-14 | Iniziato | Chardan Capital Markets | Buy |
| 2023-05-24 | Iniziato | Raymond James | Strong Buy |
Mostra tutto
Zura Bio Ltd Borsa (ZURA) Ultime notizie
Zura Bio’s Tibulizumab: First Dual BAFF & IL-17 Bispecific Antibody for Complex Autoimmune Diseases, Advancing in Phase 2 Trials – Minichart - Minichart
Zura Bio updates corporate presentation; tibulizumab Phase 2 toplines, $225.6M cash (Mar 31, 2026) - TradingView
Zura Bio (NASDAQ: ZURA) furnishes updated corporate presentation for investors - Stock Titan
We're Hopeful That Zura Bio (NASDAQ:ZURA) Will Use Its Cash Wisely - simplywall.st
Zura Bio completes enrollment in tibulizumab trials By Investing.com - Investing.com South Africa
ZURA Financial Update: Cash Position and Operational Outlook - GuruFocus
Zura Bio completes Phase 2 trial enrollment for tibulizumab in hidradenitis suppurativa - Traders Union
Zura Bio clears enrollment targets in two Phase 2 studies, adds a third - Stock Titan
Zura Bio Ltd (ZURA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Zura Bio (ZURA) VP details share, RSU and option holdings - Stock Titan
Zura Bio | 4: Statement of changes in beneficial ownership of securities-Director Jarrett Jennifer - Moomoo
Zura Bio (NASDAQ: ZURA) director receives grant of 51,000 share options - Stock Titan
Zura Bio (ZURA) director awarded 51,000 share options at $3.62 - Stock Titan
Zura Bio (ZURA) director receives grant of 51,000 stock options - Stock Titan
Zura Bio (ZURA) director Amit Munshi granted 51,000 share options at $3.62 - Stock Titan
Zura Bio (ZURA) director Daniel Becker receives 51,000 share options at $3.62 - Stock Titan
Director at Zura Bio (NASDAQ: ZURA) granted 51,000 stock options - Stock Titan
Zura Bio (ZURA) director receives 51,000 share options at $3.62 strike price - Stock Titan
Zura Bio | 4: Statement of changes in beneficial ownership of securities-Director Munshi Amit - Moomoo
Zura Bio StockSaturday look at the business model and pipeline - AD HOC NEWS
Zura Bio (NASDAQ: ZURA) investors approve board slate, auditor and 2023 equity plan changes - Stock Titan
Zura Bio Ltd (ZURA) Institutional Confidence - TradingKey
Zura Bio Ltd (ZURA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Zura Bio Ltd (ZURA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Zura Bio Ltd (ZURA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Zura Bio Ltd (ZURA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Zura Bio Ltd (ZURA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Zura Bio Ltd (ZURA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Zura Bio Ltd (ZURA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Zura Bio Ltd stock (KYG989201089): Pipeline update and capital raise reshape the story - AD HOC NEWS
Here's Why We're Not Too Worried About Zura Bio's (NASDAQ:ZURA) Cash Burn Situation - Yahoo Finance
ZURAZura Bio Ltd Stock Price and Quote - Finviz
Zura Bio (NASDAQ: ZURA) discloses resignation of director Someit Sidhu - Stock Titan
Zura Bio Ltd stock (KYG989201089): pipeline update keeps autoimmune story in focus - AD HOC NEWS
Venrock entities report 9.99% ownership in ZURA (ZURA) - Stock Titan
Great Point Partners, Dr. Jay & Nordahl report 4.44% in ZURA (ZURA) - Stock Titan
Zura Bio reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Zura Bio stock (KYG989201089): Appoints Muzammil Mustufa as Chief Business Officer - AD HOC NEWS
Zura Bio's new CBO gets options on 600,000 shares at $4.80 - Stock Titan
Zura Bio appoints Muzammil Mustufa as chief business officer By Investing.com - Investing.com Canada
Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer - ChartMill
TradingKey - TradingKey
Suvretta/Averill disclose large ZURA stakes (NASDAQ: ZURA) in 13G/A filing - Stock Titan
Jessica Chen - White & Case LLP
Zura Bio Limited (NASDAQ:ZURA) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Insider Purchases Worth US$12.5m See Losses As Zura Bio Market Value Drops To US$464m - simplywall.st
Zura Bio Ltd 1Q 2026: Net income $(24.2M), EPS $(0.22) — 10-Q Summary - TradingView
Zura Bio (Nasdaq: ZURA) widens Q1 loss, boosts cash to $225.6M - Stock Titan
Zura Bio (NASDAQ: ZURA) boosts cash with $134.6M raise as R&D loss deepens - Stock Titan
Zura Bio Limited Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates - ChartMill
Zura Bio Ltd Azioni (ZURA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.05%
0.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):